AACR: One year after mammoth lung cancer win, Merck's Keytruda holds its own in tough-to-treat subgroups

At last year’s American Association for Cancer Research annual meeting, Merck’s Keytruda-chemo combo stole the spotlight with stellar lung cancer data. And this year, the company was back to show the regimen's results held up in historically tough-to-treat patient groups.